This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Status epilepticus, unspecifiedStatus Epilepticus, Unspecified

Contents — quick navigation
ABasic informationICD-10: G41.9 | Special Copayment Reduction: V125 | Coverage period: 5 years
BSynonymsStatus epilepticus (unspecified), status epilepticus NOS (not otherwise specified)
CAdult onsetSE occurs at all ages; bimodal incidence (high in infants and the elderly); adult SE commonly has symptomatic causes such as stroke and metabolic disorders
S1HistoryHistorical descriptions of SE, changes in definition, the ILAE 2015 classification innovation
S2CausesAcute symptomatic, remote symptomatic, progressive, idiopathic; differences in major causes by age
S3GeneticsSpectrum of major genes associated with SE; pharmacogenomic considerations
S4General epidemiologyAnnual incidence 10–41/100,000; mortality 10–22%; bimodal age distribution
S5PathophysiologyFailure of seizure termination mechanisms; GABA internalization; glutamate overactivation; systemic complications
S6SymptomsClinical spectrum of convulsive SE vs nonconvulsive SE
S7SignsEEG findings by type; signs of systemic complications
S8ScreeningEmergency testing panel; necessity of EEG; tests to identify the cause
S9DiagnosisILAE 2015 definition; Salzburg criteria; the four axes of the ILAE classification
S10TreatmentStepwise treatment algorithm; management of refractory and super-refractory SE
S11PrognosisSTESS and EMSE prognostic indicators; determinants of mortality and morbidity
S12PreventionPrimary and secondary prevention; home emergency medications; patient education
S13References10 key references

S1. History

Medical descriptions of status epilepticus (SE) date back to ancient civilizations. Babylonian medical texts (circa 700 BC) describe a state of continuous convulsions, and Hippocrates also recorded the continued occurrence of convulsions as an ominous sign. However, the modern concept of SE was formed in the 19th century.

In 1824, the French physician Louis-Florentin Calmeil first formally used the term "état de mal épileptique," and in 1876 William Richard Gowers described in detail the clinical features and natural course of SE, contributing to the recognition of SE as a neurological emergency. The introduction of EEG technology in the early 20th century made accurate diagnosis and classification of SE possible.

The definition of SE has changed historically. Until the 1960s, "a seizure lasting 30 minutes or longer" was the standard definition. This 30-minute criterion reflected the time at which neuronal injury begins in animal experiments. However, clinical epidemiological studies confirmed that tonic-clonic seizures lasting 5 minutes or longer very rarely terminate spontaneously, so a 5-minute criterion was introduced as a practical time to start treatment.

In 2015, the ILAE Task Force published a comprehensive definition and classification of SE. This classification introduced a four-axis system: (1) classification by seizure type, (2) classification by etiology, (3) classification by EEG correlates and (4) classification by age. It also supported clinical decision-making by setting two time criteria (T1: start of treatment, T2: effect on long-term outcome) for each seizure type. This classification system is still used as the international standard for clinical research and practice in SE.

Increased recognition of nonconvulsive SE (NCSE) came along with advances in continuous EEG monitoring technology beginning in the 1990s. The development of the Salzburg EEG criteria in 2013 contributed to standardizing the diagnosis of NCSE, and several subsequent studies validated the sensitivity (97.7%) and specificity (89.6%) of these criteria.

S2. Causes

The causes of SE are broadly classified as acute symptomatic, remote symptomatic, progressive, and idiopathic/cryptogenic.

Major causes by age

Age groupMajor causes
Neonates (0–28 days)Hypoxic-ischemic encephalopathy, hypoglycemia, hypocalcemia, intracranial hemorrhage, inborn errors of metabolism, meningitis
Infants (1–12 months)Infantile spasms (West syndrome), febrile seizures, encephalitis, congenital brain structural abnormalities
Children (1–12 years)Febrile status epilepticus, exacerbation of underlying epilepsy (such as LGS), encephalitis, head trauma
Adolescents/adults (13–60 years)Discontinuation of antiseizure medication, autoimmune encephalitis, brain tumor, alcohol-related, head trauma
Elderly (>60 years)Stroke, dementia, metabolic abnormalities (hypoglycemia, hyponatremia), drug toxicity, neurodegenerative diseases

Proportion by cause category (adults)

S3. Genetics

SE is not a single genetic disease, but genetic predisposition has an important influence on susceptibility to SE.

Major genes associated with SE

GeneAssociated diseaseSE type
SCN1ADravet syndrome, GEFS+Febrile tonic-clonic SE, fever-triggered
POLG1Alpers syndromeRefractory myoclonic SE; valproate contraindicated
TSC1/TSC2Tuberous sclerosisInfantile spasms, SE associated with LGS
CDKL5CDKL5 deficiency disorderEarly-onset refractory SE
STXBP1Ohtahara syndromeNeonatal SE, early infantile SE
GRIN2ASleep-related epilepsyFrontal lobe SE during sleep
EPM2A/NHLRC1Lafora body diseaseProgressive myoclonic SE

Pharmacogenomics

CYP2C9/CYP2C19 polymorphisms affect the metabolism of phenytoin and valproate and are relevant to predicting serum concentrations and adjusting doses. HLA-B*15:01/HLA-A*31:01 testing is used to prevent carbamazepine-associated severe cutaneous reactions. Such pharmacogenomic information is becoming increasingly important for optimizing SE treatment.

S4. General epidemiology

SE is one of the most common neurological emergencies. Pooling large epidemiological studies from the United States and Europe, the annual incidence is reported as 10–41 per 100,000 population. In the United States, about 150,000 cases of SE occur annually, of which about 42,000 patients are estimated to die.

Bimodal age distribution of incidence

The incidence of SE is markedly higher in infancy (under 1 year of age) and old age (60 years and older). The main causes of SE in infancy are febrile SE, congenital brain structural abnormalities and inborn errors of metabolism, and the main causes of SE in old age are stroke, metabolic abnormalities and dementia-related seizures.

Mortality and morbidity

Epidemiology in Korea

In university hospital–based studies in Korea, the annual incidence of SE is reported to be at a level similar to that of Western countries, and with entry into an aging society, the proportion of post-stroke SE and SE of metabolic cause is increasing.

S5. Pathophysiology

The pathophysiology of SE can be summarized as failure of the normal seizure termination mechanisms. Normally, seizures terminate spontaneously through mechanisms such as strengthening of GABA-ergic inhibition, neuronal fatigue and synaptic depletion. In SE, these termination mechanisms fail, or the seizure persists in a self-sustaining manner because of a pathological state.

Molecular-level mechanisms

Pathophysiology of systemic complications

Early SE (0–30 minutes): autonomic nervous system overactivation raises blood pressure, heart rate and blood glucose. Late SE (>30 minutes): elevated body temperature from muscle activity, lactic acidosis, myoglobinuria and kidney failure due to rhabdomyolysis, respiratory depression and pulmonary aspiration, and decreased blood glucose occur, worsening brain injury.

S6. Symptoms

The clinical symptoms of SE differ greatly depending on seizure type. G41.9 (unspecified) is a code used when the type is difficult to classify clearly or as a temporary code before the final type classification.

Convulsive SE (GCSE)

Generalized tonic-clonic convulsions lasting 5 minutes or longer, or repeated seizures without recovery of consciousness between them. It is the type that is clinically easiest to recognize.

Nonconvulsive SE (NCSE)

A state of persistent impairment of consciousness without convulsions, which is difficult to recognize clinically. It includes absence SE (ASE), complex partial SE (CPSE), subtle SE and electrographic-only SE. NCSE should always be differentiated in patients with unexplained impaired consciousness in the emergency department or intensive care unit.

Clinical warning signs

S7. Signs

Classification of EEG findings (ILAE 2015)

EEG patternFeaturesClinical significance
Continuous seizure dischargesMonotonous or complex rhythmic discharges; >10 secondsConvulsive or nonconvulsive SE
Intermittent seizure dischargesAlternation of seizure discharges and suppressionPossible nonconvulsive SE; judged according to context
Burst-suppression patternAlternation of high-amplitude bursts and electrical silenceSevere brain injury; anesthesia-induced state
Periodic discharges (LPD, GPD)Lateralized/generalized periodic dischargesLocated at the boundary between SE and interictal abnormality

Signs of systemic complications

S8. Screening

In patients with suspected or confirmed SE, the following screening tests are performed immediately.

Tests to perform immediately (emergency)

Additional tests (after stabilization)

S9. Diagnosis

ILAE 2015 definition

Status epilepticus (SE) is defined as "a condition resulting from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms that lead to abnormally prolonged seizures (persisting beyond time point T1)." In convulsive SE, T1 (the criterion for starting treatment) is 5 minutes, and T2 (the point at which long-term damage is possible) is 30 minutes.

The four-axis system of the ILAE 2015 classification

Salzburg criteria (nonconvulsive SE)

Salzburg EEG criteria for the diagnosis of nonconvulsive SE (2013):

Diagnosis by treatment response (ex juvantibus)

In doubtful cases, a trial administration of a benzodiazepine (a small dose of lorazepam) with simultaneous confirmation of EEG improvement and clinical response can be used as a diagnostic aid.

S10. Treatment

SE treatment follows a staged protocol. If there is no response to treatment at each stage, proceed promptly to the next stage.

Stepwise treatment algorithm

Immediate measures (0 minutes): Secure ABCs (airway, breathing, circulation), administer oxygen, establish IV access, measure and correct blood glucose, monitor vital signs, attach EEG (if possible)

Stage 1 — Initial treatment (within 5 minutes): Lorazepam IV 0.1 mg/kg (max 4 mg) / midazolam IM 0.2 mg/kg (max 10 mg) / diazepam rectal 0.2–0.5 mg/kg

Stage 2 — Second-line drugs (20–40 minutes): Fosphenytoin 20 mg PE/kg IV (maximum 150 mg PE/min) / valproate 30–40 mg/kg IV (contraindicated if POLG disease is suspected) / levetiracetam 60 mg/kg IV (max 4,500 mg) / lacosamide 200–400 mg IV (especially consider in focal SE)

Stage 3 — Refractory SE (30–60 minutes): Midazolam continuous infusion 0.05–0.4 mg/kg/h / propofol 1–2 mg/kg loading followed by 1–5 mg/kg/h (adults, within 48 hours) / phenobarbital 15–20 mg/kg IV / ICU admission and cEEG monitoring

Stage 4 — Super-refractory SE (>24–48 hours): Ketamine (NMDA receptor antagonist) / inhalational anesthetic (isoflurane) / ketogenic diet / immunotherapy (autoimmune cause) / hypothermia therapy / neurosurgery (focal lesion)

Treatment in special situations

SituationSpecific treatment
Hypoglycemic SE50% glucose 50 mL IV; thiamine 100 mg IV (in alcohol-dependent patients)
Isoniazid toxicityPyridoxine (vitamin B6) 5 g IV
Eclampsia in pregnancyMagnesium sulfate IV; delivery planned after the mechanism occurs
POLG-related SEValproate contraindicated; choose levetiracetam or lacosamide
Autoimmune SEIV immunoglobulin, steroids, plasma exchange; consider rituximab

S11. Prognosis

The prognosis of SE is determined by multiple factors, including the underlying disease, duration of SE, patient age and promptness of treatment.

Prognostic prediction tools

Major prognostic determinants

FactorEffect
Underlying diseaseWorse in the order of acute symptomatic (stroke, hypoxia) > remote symptomatic > idiopathic
Duration of SE>30 minutes: increased risk of neuronal injury; >2 hours: poor prognosis
Patient ageThe older the patient, the higher the mortality; pediatric febrile SE is relatively favorable
Promptness of treatmentOutcomes improve when treatment is started within 5 minutes
RefractorinessRefractory SE (RSE): mortality 15–25%; super-refractory (SRSE): >30%

In long-term follow-up of SE survivors, new-onset epilepsy (symptomatic epilepsy), cognitive decline and reduced quality of life are observed. A long-term follow-up study (FEBSTAT study) on the possibility of developing temporal lobe epilepsy after febrile status epilepticus is under way.

S12. Prevention

Primary prevention (preventing the occurrence of SE)

Secondary prevention (preventing recurrence of SE)

S13. References

  1. Trinka E, et al. A definition and classification of status epilepticus — Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523. doi:10.1111/epi.13121. PMID: 26336950.
  2. Brophy GM, et al. Guidelines for the Evaluation and Management of Status Epilepticus. Neurocrit Care. 2012;17(1):3-23. PMID: 22528274.
  3. Leitinger M, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol. 2016;15(10):1054-1062. PMID: 27571157.
  4. Kapur J, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus (ESETT). N Engl J Med. 2019;381(22):2103-2113. PMID: 31774955.
  5. Silbergleit R, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus (RAMPART). N Engl J Med. 2012;366(7):591-600. PMID: 22335736.
  6. Rossetti AO, et al. Predicting survival with good neurological recovery at hospital admission after witnessed cardiac arrest. J Neurol Neurosurg Psychiatry. 2008;79(8):905-910. PMID: 18184982.
  7. DeLorenzo RJ, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029-1035. PMID: 8780085.
  8. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338(14):970-976. PMID: 9521986.
  9. Rossetti AO, et al. Prediction of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology. 2009;72(8):744-749. PMID: 19237706.
  10. Hirsch LJ, et al. American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2021 Version. J Clin Neurophysiol. 2021;38(1):1-29. PMID: 33476167.